Regulation of dimethyl-fumarate toxicity by proteasome inhibitors

References

• Field KM, Rosenthal MA, Yilmaz M, Tacey M, Drummond K. Comparison between poor and long-term survivors with glioblastoma: review of an Australian data set. Asia Pac J Clin Oncol 2013; 10:153-61 [Epub ahead of print]; PMID:23701649
   PubMed Web of Science ®Google Scholar
• Juratli TA, Schackert G, Krex D. Current status of local therapy in malignant gliomas–A clinical review of three selected approaches. Pharmacol Ther 2013; 139:341-58; PMID:23694764; http://dx.doi.org/10.1016/j.pharmthera.2013.05.003
   PubMed Web of Science ®Google Scholar
• Belge K, Brück J, Ghoreschi K. Advances in treating psoriasis. F1000Prime Rep 2014; 6:4. eCollection.
   PubMedGoogle Scholar
• Phillips JT, Fox RJ. BG-12 in multiple sclerosis. Semin Neurol 2013; 33:56-65; PMID:23709213; http://dx.doi.org/10.1055/s-0033-1343796
   PubMed Web of Science ®Google Scholar
• Linker RA, Lee DH, Ryan S, Van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134:678-692; PMID:21354971; http://dx.doi.org/10.1093/brain/awq386
   PubMed Web of Science ®Google Scholar
• Schmidt MM, Dringen R. Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem. Int., 2010; 57:460-467; http://dx.doi.org/10.1016/j.neuint.2010.01.006
   PubMed Web of Science ®Google Scholar
• Li XN, Du ZW, Huang Q, Wu JQ. Growth-inhibitory and differentiation-inducing activity of dimethylformamide in cultured human malignant glioma cells. Neurosurgery 1997; 40:1250-8; PMID:9179899; http://dx.doi.org/10.1097/00006123-199706000-00027
   PubMed Web of Science ®Google Scholar
• Ghods AJ, Glick R, Braun D, Feinstein D. Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas. Surg Neurol Int 2013; 4:160; PMID: 24404403; http://dx.doi.org/10.4103/2152-7806.123656
   PubMedGoogle Scholar
• Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367:1098-107; PMID:22992073; http://dx.doi.org/10.1056/NEJMoa1114287
   PubMed Web of Science ®Google Scholar
• Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, et al. BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372:1463-72; PMID:18970976; http://dx.doi.org/10.1016/S0140-6736(08)61619-0
   PubMed Web of Science ®Google Scholar
• Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation 2010; 19:7- 30.
   Google Scholar
• Lin SX, Lisi L, Dello Russo C, Polak PE, Sharp A, Weinberg G, Kalinin S, Feinstein DL. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro 2011; 3. pii:e00055; http://dx.doi.org/10.1042/AN20100033
   Google Scholar
• Foresti R, Bains SK, Pitchumony TS, de Castro Brás LE, Drago F, Dubois-Randé JL, Bucolo C, Motterlini R. Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. Pharmacol Res 2013; 76:132-48; PMID:23942037; http://dx.doi.org/10.1016/j.phrs.2013.07.010
   PubMed Web of Science ®Google Scholar
• Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012; 341:274-84; PMID:22267202; http://dx.doi.org/10.1124/jpet.111.190132
   PubMed Web of Science ®Google Scholar
• Moharregh-Khiabani D, Linker RA, Gold R, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol 2009; 7:60-4; PMID:19721818; http://dx.doi.org/10.2174/157015909787602788
   PubMed Web of Science ®Google Scholar
• Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ. Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. J Neurooncol 2012; 107:61-7; PMID:22037799; http://dx.doi.org/10.1007/s11060-011-0725-z
   PubMed Web of Science ®Google Scholar
• Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, Shimaoka H, Ogawa N, Mashimo K, Fujiwara D, Takeda T, et al. Inhibition of the tumour necrosis factor-alpha autocrine loop enhances the sensitivity of multiple myeloma cells to anticancer drugs. Eur J Cancer 2013; 49:3708-17; PMID:23932230; http://dx.doi.org/10.1016/j.ejca.2013.07.010
   PubMed Web of Science ®Google Scholar
• Bedford L, Lowe J, Dick LR, Mayer RJ Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 2011; 10:29-46; PMID:21151032; http://dx.doi.org/10.1038/nrd3321
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110:3281-90; PMID: 17591945; http://dx.doi.org/10.1182/blood-2007-01-065888
   PubMed Web of Science ®Google Scholar
• Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, et al. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol 2011; 86:484-7; PMID:21477075; http://dx.doi.org/10.1111/j.1600-0609.2011.01602.x
   PubMed Web of Science ®Google Scholar
• Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003; 278:33714-23; PMID: 12821677; http://dx.doi.org/10.1074/jbc.M302559200
   PubMed Web of Science ®Google Scholar
• Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004; 24:9695-704; PMID:15509775; http://dx.doi.org/10.1128/MCB.24.22.9695-9704.2004
   PubMed Web of Science ®Google Scholar
• Yu C, Rahmani M, Dent P, Grant S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 2004; 295:555-66; PMID:15093752; http://dx.doi.org/10.1016/j.yexcr.2004.02.001
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010; 115:4478-87; PMID: 20233973; http://dx.doi.org/10.1182/blood-2009-12-257261
   PubMed Web of Science ®Google Scholar
• Li C, Chen S, Yue P, Deng X, Lonial S, Khuri FR, Sun SY. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem 2010; 285:16096-104; PMID:20335171; http://dx.doi.org/10.1074/jbc.M109.072694
   PubMed Web of Science ®Google Scholar
• Peng H, Guerau-de-Arellano M, Mehta VB, Yang Y, Huss DJ, Papenfuss TL, Lovett-Racke AE, Racke MK. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK12) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem 2012; 287:28017-26; PMID:22733812; http://dx.doi.org/10.1074/jbc.M112.383380
   PubMed Web of Science ®Google Scholar
• Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011; 334:1081-6; PMID:22116877; http://dx.doi.org/10.1126/science.1209038
   PubMed Web of Science ®Google Scholar
• Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol 2011; 54:795-809; PMID:21145844; http://dx.doi.org/10.1016/j.jhep2010.11.005
   PubMed Web of Science ®Google Scholar
• Wek RC, Cavener DR. Translational control and the unfolded protein response. Antioxid Redox Signal 2007; 9:2357-71; PMID:17760508; http://dx.doi.org/10.1089/ars.2007.1764
   PubMed Web of Science ®Google Scholar
• Martín-Pérez R, Niwa M, López-Rivas A. ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis 2012; 17:349-63; http://dx.doi.org/10.1007/s10495-011-0673-2
   PubMed Web of Science ®Google Scholar
• Galehdar Z, Swan P, Fuerth B, Callaghan SM, Park DS, Cregan SP. Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA. J Neurosci 2010; 30:16938-48; PMID:21159964; http://dx.doi.org/10.1523/JNEUR-OSCI.1598-10.2010
   PubMed Web of Science ®Google Scholar
• Qi Y, Xia P. Cellular inhibitor of apoptosis protein-1 (cIAP1) plays a critical role in β-cell survival under endoplasmic reticulum stress: promoting ubiquitination and degradation of CEBP homologous protein (CHOP). J Biol Chem 2012; 287:32236-45; PMID:22815481; http://dx.doi.org/10.1074/jbc.M11-2.362160
   PubMed Web of Science ®Google Scholar
• Senkal CE, Ponnusamy S, Bielawski J, Hannun YA, Ogretmen B. Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6CHOP arm of ER-stress-response pathways. FASEB J 2010; 24:296-308; PMID:19723703; http://dx.doi.org/10.1096/fj.09-135087
   PubMed Web of Science ®Google Scholar
• Wang FM, Chen YJ, Ouyang HJ. Regulation of unfolded protein response modulator XBP1s by acetylation and deacetylation. Biochem J 2011; 433:245-52; PMID:20955178; http://dx.doi.org/10.1042/BJ20-101293
   PubMed Web of Science ®Google Scholar
• Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008; 7:1013-30; PMID:19043451; http://dx.doi.org/10.1038/nrd2755
   PubMed Web of Science ®Google Scholar
• Sureshbabu A, Bhandari V. Targeting mitochondrial dysfunction in lung diseases: emphasis on mitophagy. Front Physiol 2013; 4:384; PMID:24421769; http://dx.doi.org/10.3389/fphys.2013.00384
   PubMed Web of Science ®Google Scholar
• Yang F, Jove V, Chang S, Hedvat M, Liu L, Buettner R, Tian Y, Scuto A, Wen W, Yip ML, et al. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor. Cancer Biol Ther 2012; 13:349-57; PMID:22313636; http://dx.doi.org/10.4161/cbt.19239
   PubMed Web of Science ®Google Scholar
• Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, Chen CS, Grant S, Dent P. OSU-03012 suppresses GRP78BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biol Ther 2012; 13:224-36; PMID:22354011; http://dx.doi.org/10.4161/cbt.13.4.18877
   PubMed Web of Science ®Google Scholar
• Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, Harada H, Powis G, Chen CS, Koumenis C, et al. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 2006; 70:589-603; PMID:16622074; http://dx.doi.org/10.1124/mol.106.025007
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Cruickshanks N, Conley A, Durrant DE, Das A, Fisher PB, Kukreja RC, Grant S, Poklepovic A, et al. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal genitourinary cancer cells. Mol Pharmacol 2014; 85:408-19; PMID:24353313; http://dx.doi.org/10.1124/mol.113.090043
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Conley A, Cruickshanks N, Ridder T, Grant S, Poklepovic A, Dent P. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer Biol Ther 2014; 15:305-16; PMID:24351423; http://dx.doi.org/10.4161/cbt.27309
   PubMed Web of Science ®Google Scholar